Hypoxia has been associated with poor local tumour control and relapse in many cancer sites, including carcinoma of the prostate. This translational study tests whether breathing carbogen gas improves the oxygenation of human prostate carcinoma xenografts in mice and in human patients with prostate cancer. A total of 23 DU145 tumour-bearing mice, 17 PC3 tumour-bearing mice and 17 human patients with prostate cancer were investigated. Intrinsic susceptibility-weighted MRI was performed before and during a period of carbogen gas breathing. Quantitative R 2 * pixel maps were produced for each tumour and at each time point and changes in R 2 * induced by carbogen were determined. There was a mean reduction in R 2 * of 6.4% (P ¼ 0.003) for DU145 xenografts and 5.8% (P ¼ 0.007) for PC3 xenografts. In all, 14 human subjects were evaluable; 64% had reductions in tumour R 2 * during carbogen inhalation with a mean reduction of 21.6% (P ¼ 0.0005). Decreases in prostate tumour R 2 * in both animal models and human patients as a result of carbogen inhalation suggests the presence of significant hypoxia. The finding that carbogen gas breathing improves prostate tumour oxygenation provides a rationale for testing the radiosensitising effects of combining carbogen gas breathing with radiotherapy in prostate cancer patients. British Journal of Cancer (2009) The relationship of radiosensitivity to varying oxygenation and the detrimental effects of hypoxia in human tumours was first shown over 50 years ago (Gray et al, 1953;Tomlinson and Gray, 1955). Since then, it has been established that hypoxia is an important factor in radiotherapy treatment failure and has been associated in clinical studies with poor local tumour control and relapse in many cancer sites (Nordsmark et al, 1996;Fyles et al, 1998;Brizel et al, 1999;Movsas et al, 2002;Hoskin et al, 2003).Eppendorf microelectrode measurements have been used to invasively characterise the range and heterogeneity of oxygen partial pressures in the prostate and show that hypoxic regions exist in human prostate carcinoma (Movsas et al, 1999;Parker et al, 2004). The outcome of radical radiotherapy for prostate cancer is influenced by the presence of hypoxia. A study that prospectively analysed 57 patients with localised disease showed that hypoxic tumours had a significantly worse biochemical relapse-free survival at 2 years (31 vs 92%, Po0.0001; Movsas et al, 2002). Oxygenation status is therefore an additional prognostic factor beyond the classic prognostic factors (age, clinical stage, Gleason score and prostate-specific antigen) that predicts radiation treatment failure in prostate cancer. A modelling study based on these clinical data predicts an oxygen enhancement ratio for prostate cancer of 1.4 (95% confidence interval of 1.2-1.8) that is consistent with the in vitro OER measurements of human tumour cell lines under chronic hypoxia conditions (Wang et al, 2006). These data taken together suggest that hypoxia is likely to be a valid therapeutic target in prostate cancer.The ...